AU2020336272B2 - Thyroid hormone receptor beta agonist compounds - Google Patents
Thyroid hormone receptor beta agonist compoundsInfo
- Publication number
- AU2020336272B2 AU2020336272B2 AU2020336272A AU2020336272A AU2020336272B2 AU 2020336272 B2 AU2020336272 B2 AU 2020336272B2 AU 2020336272 A AU2020336272 A AU 2020336272A AU 2020336272 A AU2020336272 A AU 2020336272A AU 2020336272 B2 AU2020336272 B2 AU 2020336272B2
- Authority
- AU
- Australia
- Prior art keywords
- compound
- mixture
- umol
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962891078P | 2019-08-23 | 2019-08-23 | |
| US62/891,078 | 2019-08-23 | ||
| US202062967943P | 2020-01-30 | 2020-01-30 | |
| US62/967,943 | 2020-01-30 | ||
| PCT/US2020/047467 WO2021041237A1 (en) | 2019-08-23 | 2020-08-21 | Thyroid hormone receptor beta agonist compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2020336272A1 AU2020336272A1 (en) | 2022-04-14 |
| AU2020336272B2 true AU2020336272B2 (en) | 2026-07-16 |
Family
ID=74684314
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2020336272A Active AU2020336272B2 (en) | 2019-08-23 | 2020-08-21 | Thyroid hormone receptor beta agonist compounds |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US12528791B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4017875A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7646632B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN114430743A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020336272B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3154488A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021041237A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN121081472A (zh) | 2018-12-13 | 2025-12-09 | 拓臻股份有限公司 | 一种THRβ受体激动剂化合物及其制备方法和用途 |
| WO2020227549A1 (en) | 2019-05-08 | 2020-11-12 | Aligos Therapeutics, Inc. | MODULATORS OF THR-β AND METHODS OF USE THEREOF |
| CA3154488A1 (en) | 2019-08-23 | 2021-03-04 | Terns Pharmaceuticals, Inc. | Thyroid hormone receptor beta agonist compounds |
| CA3154391A1 (en) | 2019-09-12 | 2021-03-18 | Terns Pharmaceuticals, Inc. | Thyroid hormone receptor beta agonist compounds |
| EP4178672A1 (en) | 2020-07-10 | 2023-05-17 | Aligos Therapeutics, Inc. | MODULATORS OF THR-ß AND METHODS OF USE THEREOF |
| WO2022037617A1 (zh) * | 2020-08-19 | 2022-02-24 | 成都凡诺西生物医药科技有限公司 | 腈代三嗪类衍生物及其制备方法和应用 |
| JP2024510935A (ja) * | 2021-03-03 | 2024-03-12 | ターンズ・ファーマシューティカルズ・インコーポレイテッド | 甲状腺ホルモン受容体ベータアゴニスト化合物 |
| US20240239761A1 (en) * | 2021-03-19 | 2024-07-18 | Medshine Discovery Inc. | Bicyclic phenol compounds and use thereof |
| CN116940566A (zh) * | 2021-03-19 | 2023-10-24 | 南京明德新药研发有限公司 | 双环吡啶酮类化合物及其应用 |
| TW202313615A (zh) * | 2021-05-21 | 2023-04-01 | 大陸商深圳微芯生物科技股份有限公司 | 一種雜環化合物及其應用 |
| TWI910297B (zh) * | 2021-12-24 | 2026-01-01 | 大陸商廣東東陽光藥業股份有限公司 | 一種作為甲狀腺激素β受體激動劑的化合物及其用途 |
| CN113979963B (zh) * | 2021-12-24 | 2022-03-11 | 凯思凯旭(上海)医药科技有限公司 | 一种作为甲状腺激素β受体激动剂的化合物及其用途 |
| CN116354934A (zh) * | 2021-12-28 | 2023-06-30 | 中国科学院上海药物研究所 | 一类喹啉类化合物及其制备方法、药物组合物和用途 |
| PE20252787A1 (es) | 2023-04-07 | 2025-12-22 | Terns Pharmaceuticals Inc | Combinacion que comprende un agonista de thr-beta y un agonista de glp-1r para su uso en el tratamiento de un trastorno hepatico o una enfermedad cardiometabolica |
| WO2026092583A1 (en) | 2024-10-30 | 2026-05-07 | Ascletis Pharma (China) Co., Limited | Thr-beta modulators, alone or in combination with glp-1r\gipr\gcgr modulators for the treatment of metabolic diseases and alopecia areata diseases |
| CN120923503A (zh) * | 2025-10-10 | 2025-11-11 | 吉斯凯(苏州)制药有限公司 | 具有杂环结构的化合物、THRβ受体激动剂及用途 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001098256A1 (en) * | 2000-06-21 | 2001-12-27 | Karo Bio Ab | Thyroid receptor ligands, pharmaceutical compositions comprising them and their use in the treatment of disorders influenced by thyroid hormones |
| WO2007134864A1 (en) * | 2006-05-24 | 2007-11-29 | Karo Bio Ab | Indole derivatives and their use as thyroid receptor ligands |
| WO2019144835A1 (zh) * | 2018-01-23 | 2019-08-01 | 深圳市塔吉瑞生物医药有限公司 | 取代的哒嗪酮化合物 |
| WO2020073974A1 (en) * | 2018-10-12 | 2020-04-16 | Inventisbio Shanghai Ltd. | Thyroid hormone receptor agonists |
| WO2020169069A1 (en) * | 2019-02-21 | 2020-08-27 | Nanjing Ruijie Pharma Co., Ltd. | Novel compounds and their uses as thyroid hormone receptor agonists |
| WO2020227549A1 (en) * | 2019-05-08 | 2020-11-12 | Aligos Therapeutics, Inc. | MODULATORS OF THR-β AND METHODS OF USE THEREOF |
Family Cites Families (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4197307A (en) | 1977-04-12 | 1980-04-08 | Ciba-Geigy Corporation | 2-Alkylthio-, 2-alkylsulphinyl- and 2-alkylsulfonyl-6-phenylbenzimidazoles as anthelmintic agents |
| EP0377903A3 (de) | 1989-01-09 | 1991-07-17 | Bayer Ag | Substituierte Hexahydro-1,2,4-triazindione, Verfahren zu ihrer Herstellung, Zwischenprodukte dafür und ihre Verwendung |
| DE60020786T2 (de) | 1999-09-30 | 2006-03-23 | Pfizer Products Inc., Groton | 6-Azauracilderivate als Liganden der Thyroidrezeptoren |
| US6787652B1 (en) | 1999-09-30 | 2004-09-07 | Pfizer, Inc. | 6-Azauracil derivatives as thyroid receptor ligands |
| WO2002051805A1 (de) | 2000-12-27 | 2002-07-04 | Bayer Aktiengesellschaft | Indol-derivate |
| CA2473162A1 (en) | 2002-01-30 | 2003-08-07 | Kissei Pharmaceutical Co., Ltd. | Novel thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof |
| WO2003094845A2 (en) | 2002-05-08 | 2003-11-20 | Bristol-Myers Squibb Company | Pyridine-based thyroid receptor ligands |
| GB0327319D0 (en) | 2003-11-24 | 2003-12-24 | Pfizer Ltd | Novel pharmaceuticals |
| US7572799B2 (en) | 2003-11-24 | 2009-08-11 | Pfizer Inc | Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors |
| FR2882750B1 (fr) | 2005-03-03 | 2007-05-11 | Pierre Fabre Medicament Sa | Derives de 1,2,4-triazines, leur preparation et leur application en therapeutique humaine |
| GB0513692D0 (en) | 2005-07-04 | 2005-08-10 | Karobio Ab | Novel pharmaceutical compositions |
| ATE480524T1 (de) | 2005-07-21 | 2010-09-15 | Hoffmann La Roche | Pyridazinonderivate als schilddrüsenhormon- rezeptoragonisten |
| GB0608724D0 (en) | 2006-05-03 | 2006-06-14 | Karobio Ab | Novel Pharmaceutical Compositions |
| WO2007132475A1 (en) | 2006-05-15 | 2007-11-22 | Cadila Healthcare Limited | Selective tr-beta 1 agonist |
| WO2008130637A1 (en) | 2007-04-18 | 2008-10-30 | New York University | Hydrazide compounds as thyroid hormone receptor modulators and uses thereof |
| SI2170403T1 (sl) | 2007-06-27 | 2014-07-31 | Quark Pharmaceuticals, Inc. | Sestavki in postopki za inhibicijo ekspresije pro-apoptotskih genov |
| TW200906823A (en) | 2007-07-16 | 2009-02-16 | Lilly Co Eli | Compounds and methods for modulating FXR |
| US8076334B2 (en) | 2007-09-20 | 2011-12-13 | Hoffmann-La Roche Inc. | Prodrugs of thyroid hormone analogs |
| FR2933979B1 (fr) | 2008-07-15 | 2012-08-24 | Pf Medicament | Derives de triazines et uraciles, leur preparation et leur application en therapeutique humaine |
| KR101396606B1 (ko) | 2009-04-20 | 2014-05-16 | 미쓰비시 타나베 파마 코퍼레이션 | 신규 갑상선 호르몬 β 수용체 작동약 |
| WO2011038207A1 (en) | 2009-09-25 | 2011-03-31 | Metabasis Therapeutics, Inc. | Phosphorus-containing thyroid hormone receptor agonists and methods of use |
| EA023521B1 (ru) | 2011-11-14 | 2016-06-30 | Сефалон, Инк. | ПРОИЗВОДНЫЕ УРАЦИЛА В КАЧЕСТВЕ ИНГИБИТОРОВ AXL И c-MET КИНАЗЫ |
| CN103130723B (zh) | 2011-11-30 | 2015-01-14 | 成都地奥制药集团有限公司 | 一种多聚(adp-核糖)聚合酶抑制剂 |
| CN102898377B (zh) | 2012-02-14 | 2016-01-20 | 南京圣和药业股份有限公司 | 一类酞嗪酮衍生物及其用途 |
| ES2795450T3 (es) | 2012-09-17 | 2020-11-23 | Madrigal Pharmaceuticals Inc | Procedimiento para sintetizar análogos de hormonas tiroideas y polimorfos de los mismos |
| CA2944139C (en) | 2014-04-11 | 2020-11-03 | Cymabay Therapeutics, Inc. | Treatment of nafld and nash |
| CN107074823B (zh) | 2014-09-05 | 2021-05-04 | 基因泰克公司 | 治疗性化合物及其用途 |
| CN105477636B (zh) | 2015-10-16 | 2019-09-17 | 厦门大学 | 使用阿维菌素及其衍生物治疗代谢疾病的方法 |
| TWI757266B (zh) | 2016-01-29 | 2022-03-11 | 美商維它藥物有限責任公司 | ROR-γ調節劑 |
| MX2018011813A (es) | 2016-03-28 | 2019-01-24 | Intercept Pharmaceuticals Inc | Medicina obtenida mediante la combinacion de agonista fxr y arb. |
| PL3435996T3 (pl) | 2016-03-31 | 2025-07-28 | Genfit | Elafibranor do zastosowania w leczeniu pierwotnego zapalenia dróg żółciowych |
| MX2018014024A (es) | 2016-05-25 | 2019-08-29 | Akarna Therapeutics Ltd | Terapias de combinación con moduladores del receptor x farnesoide (fxr). |
| WO2018027892A1 (en) | 2016-08-12 | 2018-02-15 | Eli Lilly And Company | Amino pyrimidine ssao inhibitors |
| MX394463B (es) | 2016-10-18 | 2025-03-19 | Madrigal Pharmaceuticals Inc | Métodos para tratar trastornos del hígado o trastornos lipídicos con un agonista de thr-beta. |
| CA3041169A1 (en) | 2016-10-19 | 2018-04-26 | Boehringer Ingelheim International Gmbh | Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof |
| WO2018103624A1 (zh) | 2016-12-06 | 2018-06-14 | 江苏恒瑞医药股份有限公司 | 一种κ阿片受体激动剂在制备治疗法尼醇X受体激动剂引起的瘙痒的药物中的用途 |
| JP7618384B2 (ja) | 2017-02-21 | 2025-01-21 | ジェンフィ | Pparアゴニストとfxrアゴニストとの組合せ |
| SG11201907673YA (en) | 2017-03-13 | 2019-09-27 | Genfit | Pharmaceutical compositions for combination therapy |
| WO2018170173A1 (en) | 2017-03-15 | 2018-09-20 | Metacrine, Inc. | Farnesoid x receptor agonists and uses thereof |
| CA3058542A1 (en) | 2017-04-18 | 2018-10-25 | Genfit | Combination comprising a ppar agonist such as elafibranor and an acetyl-coa carboxylase (acc) inhibitor |
| WO2018208707A1 (en) | 2017-05-08 | 2018-11-15 | Neurovia, Inc. | Methods and compositions for treating demyelinating diseases |
| US20210121493A1 (en) | 2017-07-25 | 2021-04-29 | Cedars-Sinai Medical Center | Methods for treating liver diseases |
| SG11202000748TA (en) | 2017-08-25 | 2020-03-30 | Genfit | Non-invasive diagnostic of non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis and/or liver fibrosis |
| WO2019053235A1 (en) | 2017-09-15 | 2019-03-21 | Genfit | NON-INVASIVE DIAGNOSIS OF NON ALCOHOLIC LIVER DISEASES, NON ALCOHOLIC STHEATHEPATITIS AND / OR HEPATIC FIBROSIS |
| EP3684954B1 (en) | 2017-09-18 | 2025-11-26 | Genfit | Non-invasive diagnostic of non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis and/or liver fibrosis |
| US11168079B2 (en) | 2017-11-01 | 2021-11-09 | Bristol-Myers Squibb Company | Alkene compounds as farnesoid x receptor modulators |
| US20200340060A1 (en) | 2017-11-13 | 2020-10-29 | Gilead Sciences, Inc. | Compositions and methods for identifying and treating liver diseases and monitoring treatment outcomes |
| KR20210002573A (ko) | 2018-04-24 | 2021-01-08 | 주식회사 피에이치파마 | 간 질환에 호중구 엘라스타제 저해제의 사용 |
| ES3029158T3 (en) | 2018-06-12 | 2025-06-23 | Xizang Haisco Pharmaceutical Co Ltd | Thyroid hormone receptor agonists and uses thereof |
| WO2020041741A1 (en) | 2018-08-24 | 2020-02-27 | Terns, Inc. | Thyroid hormone receptor beta agonist compounds |
| EP3844156A4 (en) | 2018-08-30 | 2022-06-08 | Terns Pharmaceuticals, Inc. | TREATMENT OF LIVER DISEASES |
| NZ773110A (en) | 2018-09-18 | 2024-11-29 | Terns Inc | Compounds for treating certain leukemias |
| US20220047553A1 (en) | 2018-09-18 | 2022-02-17 | Metacrine, Inc. | Farnesoid x receptor agonists for the treatment of disease |
| TWI884745B (zh) | 2018-10-12 | 2025-05-21 | 美商拓臻股份有限公司 | 甲狀腺素受體β促效劑化合物 |
| CN121081472A (zh) | 2018-12-13 | 2025-12-09 | 拓臻股份有限公司 | 一种THRβ受体激动剂化合物及其制备方法和用途 |
| WO2020131578A2 (en) | 2018-12-17 | 2020-06-25 | Mitopower Llc | Nicotinyl riboside compounds and their uses |
| CN111484481A (zh) | 2019-01-26 | 2020-08-04 | 察略盛医药科技(上海)有限公司 | 哒嗪酮类衍生物、其制备方法及其在医药上的用途 |
| WO2020228577A1 (zh) | 2019-05-10 | 2020-11-19 | 深圳微芯生物科技股份有限公司 | 一种哒嗪酮衍生物及其应用 |
| WO2020239076A1 (zh) | 2019-05-29 | 2020-12-03 | 南京明德新药研发有限公司 | 作为甲状腺素受体-β激动剂的哒嗪酮类衍生物及其应用 |
| TW202114672A (zh) | 2019-07-23 | 2021-04-16 | 瑞士商諾華公司 | 使用fxr促效劑的肝臟疾病之組合治療 |
| CN112409340B (zh) | 2019-08-21 | 2022-03-18 | 海创药业股份有限公司 | 卤素取代的苯醚类化合物及其用途 |
| CA3154488A1 (en) | 2019-08-23 | 2021-03-04 | Terns Pharmaceuticals, Inc. | Thyroid hormone receptor beta agonist compounds |
| CA3154391A1 (en) | 2019-09-12 | 2021-03-18 | Terns Pharmaceuticals, Inc. | Thyroid hormone receptor beta agonist compounds |
| WO2021121210A1 (zh) | 2019-12-16 | 2021-06-24 | 江苏恒瑞医药股份有限公司 | 并环类衍生物、其制备方法及其在医药上的应用 |
| WO2021231646A1 (en) | 2020-05-13 | 2021-11-18 | Terns Pharmaceuticals, Inc. | Combination treatment of liver disorders |
| WO2021231644A1 (en) | 2020-05-13 | 2021-11-18 | Terns Pharmaceuticals, Inc. | Combination treatment of liver disorders |
| US20220135540A1 (en) | 2020-10-15 | 2022-05-05 | Eli Lilly And Company | Polymorphs of an fxr agonist |
| CN114437034A (zh) | 2020-11-06 | 2022-05-06 | 深圳微芯生物科技股份有限公司 | 一种酞嗪类化合物的可药用盐、晶型及其制备方法 |
| MX2023008365A (es) | 2021-01-14 | 2023-10-04 | Enyo Pharma | Efecto sinérgico de un agonista de fxr e ifn para el tratamiento de infección por hbv. |
| JP2024510935A (ja) | 2021-03-03 | 2024-03-12 | ターンズ・ファーマシューティカルズ・インコーポレイテッド | 甲状腺ホルモン受容体ベータアゴニスト化合物 |
| US20240239761A1 (en) | 2021-03-19 | 2024-07-18 | Medshine Discovery Inc. | Bicyclic phenol compounds and use thereof |
| MX2024005647A (es) | 2021-11-11 | 2024-05-24 | Terns Pharmaceuticals Inc | Tratamiento de trastornos hepaticos con un agonista del thr-\03b2. |
| AU2022387121A1 (en) | 2021-11-11 | 2024-06-20 | Terns Pharmaceuticals, Inc. | Combination of a ssao inhibitor and thr-beta agonist for use in the treatment of liver disorders |
| US20230181583A1 (en) | 2021-11-11 | 2023-06-15 | Terns Pharmaceuticals, Inc. | Treating liver disorders with an ssao inhibitor |
| WO2023220404A1 (en) | 2022-05-13 | 2023-11-16 | Terns Pharmaceuticals, Inc. | Treatment of non-alcoholic steatohepatitis |
| PE20252787A1 (es) | 2023-04-07 | 2025-12-22 | Terns Pharmaceuticals Inc | Combinacion que comprende un agonista de thr-beta y un agonista de glp-1r para su uso en el tratamiento de un trastorno hepatico o una enfermedad cardiometabolica |
-
2020
- 2020-08-21 CA CA3154488A patent/CA3154488A1/en active Pending
- 2020-08-21 EP EP20856291.8A patent/EP4017875A4/en active Pending
- 2020-08-21 AU AU2020336272A patent/AU2020336272B2/en active Active
- 2020-08-21 US US17/637,426 patent/US12528791B2/en active Active
- 2020-08-21 JP JP2022512349A patent/JP7646632B2/ja active Active
- 2020-08-21 CN CN202080066442.XA patent/CN114430743A/zh active Pending
- 2020-08-21 WO PCT/US2020/047467 patent/WO2021041237A1/en not_active Ceased
-
2025
- 2025-03-05 JP JP2025034294A patent/JP2025106242A/ja active Pending
- 2025-12-19 US US19/426,869 patent/US20260226033A1/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001098256A1 (en) * | 2000-06-21 | 2001-12-27 | Karo Bio Ab | Thyroid receptor ligands, pharmaceutical compositions comprising them and their use in the treatment of disorders influenced by thyroid hormones |
| WO2007134864A1 (en) * | 2006-05-24 | 2007-11-29 | Karo Bio Ab | Indole derivatives and their use as thyroid receptor ligands |
| WO2019144835A1 (zh) * | 2018-01-23 | 2019-08-01 | 深圳市塔吉瑞生物医药有限公司 | 取代的哒嗪酮化合物 |
| WO2020073974A1 (en) * | 2018-10-12 | 2020-04-16 | Inventisbio Shanghai Ltd. | Thyroid hormone receptor agonists |
| WO2020169069A1 (en) * | 2019-02-21 | 2020-08-27 | Nanjing Ruijie Pharma Co., Ltd. | Novel compounds and their uses as thyroid hormone receptor agonists |
| WO2020227549A1 (en) * | 2019-05-08 | 2020-11-12 | Aligos Therapeutics, Inc. | MODULATORS OF THR-β AND METHODS OF USE THEREOF |
Also Published As
| Publication number | Publication date |
|---|---|
| US20220281849A1 (en) | 2022-09-08 |
| AU2020336272A1 (en) | 2022-04-14 |
| US12528791B2 (en) | 2026-01-20 |
| JP7646632B2 (ja) | 2025-03-17 |
| CN114430743A (zh) | 2022-05-03 |
| EP4017875A4 (en) | 2023-05-03 |
| WO2021041237A1 (en) | 2021-03-04 |
| JP2025106242A (ja) | 2025-07-15 |
| EP4017875A1 (en) | 2022-06-29 |
| JP2022544714A (ja) | 2022-10-20 |
| US20260226033A1 (en) | 2026-08-06 |
| CA3154488A1 (en) | 2021-03-04 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HB | Alteration of name in register |
Owner name: TERNS PHARMACEUTICALS, INC. Free format text: FORMER NAME(S): TERNS, INC. |